Bloomios begins trading on OTCQB Venture Marketplace as BLMS as sales of hemp-derived cannabinoid products exceed $8 million

SANTA BARBARA, Calif., March 15, 2022 /PRNewswire/ — Bloomios, Inc. (OTCQB: BLMS), a leading researcher, manufacturer and wholesaler of hemp-derived cannabinoid nutraceuticals and cosmetics, will begin trading on the OTCQB® Venture Market under the ticker symbol BLMS when the market opens today. .

(PRNewsfoto/Bloomios, Inc.)

Over the past year, Bloomios has quickly become one of the leading manufacturers of private label and white label hemp-derived cannabinoid products. This includes nutraceuticals and cosmetics that contain cannabidiol (CBD), the most popular cannabinoid of over 100 distinct cannabinoids that can be derived from hemp.

Bloomios also produces products containing alternative cannabinoids and peripheral components of hemp that share similar health benefits with CBD, such as cannabigerol (CBG) for pain management and cannabinol (CBN) for sleep, as well as terpenes (or flavonoids) that create a beneficial environment. effect for the user.

Since the official launch of Bloomios in the fourth quarter of 2020, gross revenue has grown from virtually zero to a total of more than $8 million by September 30, 2021demand exceeding supply.

Following the expansion of its facilities and the upgrading of its equipment, Bloomios has increased its production capacity by approximately 300%. Bloomios products are now distributed by hundreds of corporate customers across the United States

“As a fully-disclosed emerging growth company, our listing on the OTCQB significantly raises our profile in the market, provides greater liquidity and helps broaden our shareholder base,” said Bloomios CEO, Michael Hill. “The listing represents a major step in our long-term capital markets strategy, designed to create shareholder value and leverage our unique B2B value proposition in the growing field of hemp derivatives. “

Bloomios is targeting a North American CBD market that is projected grow at a compound annual growth rate (CAGR) of 33.3% to reach $61.3 billion by 2027, with the alternative cannabinoids market expected grow at a CAGR of 20.1% to reach $26.2 billion by 2028.

The company is also looking to expand further into the high-margin nutraceuticals space which is also experiencing phenomenal growth, and it is currently evaluating several accretive M&A targets.

For more company information, visit or contact Ron both Where Justin Lumley at (949) 432-7557 or [email protected]

About Bloomios
Bloomios, Inc. researches, manufactures, markets and distributes cannabinoid supplements and hemp-derived cosmetics in the United States through wholesale distribution channels and its wholly owned subsidiary, Bloomios Private Label. The Company provides custom formulation, brand development, manufacturing and order fulfillment to a wide variety of customers, including small and large brands, chain stores, vape shops and distributors. It offers private and white label customers a collection of over 200 customizable hemp products in 12 categories.

Bloomios is headquartered in Santa Barbara, Californiawith manufacturing and distribution in Daytona Beach, Florida.

To learn more,

Safe Harbor Statement
The matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate”, “believe”, “estimate”, “may”, “intend”, “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements. These forward-looking statements are based in large part on the Company’s expectations and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties associated with including the sale of the Company’s identity protection software products in various channels and market sectors, the issuance of the Company’s pending patent applications, COVID-19, and the impact of the economic crisis, competitive and other factors affecting the Company and its operations, markets, product and distributor performance, impact on national and local economies resulting from terrorist actions and subsequent U.S. actions ; and other factors detailed in the reports filed by the Company.

Contact with Investor Relations:
Ronald both Where Justin Lumley
CMA Investor Relations
Tel (949) 432-7566
E-mail address

Media Contact:
Tim Randall
CMA Media Relations
Tel (949) 432-7572
Contact us by email



Show original content to download multimedia: 301502091.html

SOURCE Bloomios, Inc.

Comments are closed.